- Home
- AAT vs SLNO Comparison
AAT vs SLNO Comparison
Compare AAT & SLNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AAT
- SLNO
- Stock Information
- Founded
- AAT 1967
- SLNO 1999
- Country
- AAT United States
- SLNO United States
- Employees
- AAT N/A
- SLNO N/A
- Industry
- AAT Real Estate Investment Trusts
- SLNO Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- AAT Real Estate
- SLNO Health Care
- Exchange
- AAT Nasdaq
- SLNO Nasdaq
- Market Cap
- AAT 1.7B
- SLNO 1.9B
- IPO Year
- AAT 2011
- SLNO 2014
- Fundamental
- Price
- AAT $25.99
- SLNO $45.18
- Analyst Decision
- AAT Hold
- SLNO Strong Buy
- Analyst Count
- AAT 2
- SLNO 6
- Target Price
- AAT $26.00
- SLNO $74.83
- AVG Volume (30 Days)
- AAT 352.0K
- SLNO 788.7K
- Earning Date
- AAT 02-04-2025
- SLNO 11-06-2024
- Dividend Yield
- AAT 5.15%
- SLNO N/A
- EPS Growth
- AAT 17.42
- SLNO N/A
- EPS
- AAT 0.97
- SLNO N/A
- Revenue
- AAT $452,499,000.00
- SLNO N/A
- Revenue This Year
- AAT N/A
- SLNO N/A
- Revenue Next Year
- AAT N/A
- SLNO N/A
- P/E Ratio
- AAT $26.88
- SLNO N/A
- Revenue Growth
- AAT 5.13
- SLNO N/A
- 52 Week Low
- AAT $20.03
- SLNO $35.70
- 52 Week High
- AAT $29.15
- SLNO $60.92
- Technical
- Relative Strength Index (RSI)
- AAT 34.24
- SLNO 32.12
- Support Level
- AAT $25.42
- SLNO $43.32
- Resistance Level
- AAT $28.02
- SLNO $48.51
- Average True Range (ATR)
- AAT 0.60
- SLNO 2.09
- MACD
- AAT -0.29
- SLNO -0.38
- Stochastic Oscillator
- AAT 18.04
- SLNO 20.44
About AAT American Assets Trust Inc.
American Assets Trust Inc is a self-administered real estate investment trust based in the United States. The company invests in, operates, and develops retail, office, residential, and mixed-use properties. Properties are predominantly located in South California, Northern California, Oregon, Washington, and Hawaii. American Assets operates through four segments based on property type: retail; office; mixed-use, which consists of retail and hotel components; and multifamily, which includes the company's apartment properties. The retail and office segments collectively contribute the majority of the total revenue.
About SLNO Soleno Therapeutics Inc.
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.